[The effect of isradipine on the central and cerebral hemodynamics of patients with circulatory encephalopathy and hypertension].
The new dihydropyridine calcium antagonist isradipine versus nifedipine was tested in 41 patients with essential hypertension and cerebrovascular insufficiency. The tests have shown that isradipine shows all hemodynamic effects by significantly improving cerebral blood flow and it is better tolerated than nifedipine. It is concluded that isradipine is an effective agent in the long-term management of hypertensive patients at a high risk for cerebral hypoperfusion.
Lepakhin
V K
VK
Ivleva
A Ia
AIa
Romashova
M F
MF
Udotova
S A
SA
Zubovskiĭ
L G
LG
D000328:Adult; D000368:Aged; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000503:physiopathology; D002908:Chronic Disease; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D017275:Isradipine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use
D009543:Nifedipine; D017275:Isradipine
Vliianie isradipina na tsentral'nuiu i tserebral'nuiu gemodinamiku u bol'nykh s distsirkuliatornoĭ éntsefalopatieĭ i gipertonieĭ.